32 results about "Disease/disorder" patented technology

The method for genome analysis translates the clinical findings in the patient into a comprehensive test order for genes that can be causative of the patient's illness, delimits analysis of variants identified in the patient's genome to those that are “on target” for the patient's illness, and provides clinical annotation of the likely causative variants for inclusion in a variant warehouse that is updated as a result of each sample that is analyzed and that, in turn, provides a source of additional annotation for variants. The method uses a genome sequence having the steps of entering at least one clinical feature of a patient by an end-user, assigning a weighted value to the term based on the probability of the presence of the term, mapping the term to at least one disease by accessing a knowledge base containing a plurality of data sets, wherein the data sets are made up of associations between (i) clinical features and diseases, (ii) diseases and genes, (iii) genes and genetic variants, and (iv) diseases and gene variants, assigning a truth value to each of the mapped terms based on the associated data sets and the weighted value, to provide a list of results of possible diagnoses prioritized based on the truth values, with continuous adjustment of the weightings of associations in the knowledge base based on updating of each discovered diagnosis and attendant clinical features, genes and gene variants. This method can be performed in fifty hours or twenty-four hours or less.

The present invention is directed to T-cell epitope delivering polypeptides which deliver one or more CD8+ T-cell epitopes to the MHC class I presentation pathway of a cell, including toxin-derived polypeptides which comprise embedded T-cell epitopes and are de-immunized. The present invention provides cell-targeted, CD8+ T-cell epitope delivering molecules for the targeted delivery of cytotoxicity to certain cells, e.g., infected or malignant cells, for the targeted killing of specific cell types, and the treatment of a variety of diseases, disorders, and conditions, including cancers, immune disorders, and microbial infections. The present invention also provides methods of generating polypeptides capable of delivering one or more heterologous T-cell epitopes to the MHC class I presentation pathway, including polypeptides which are 1) B-cell and / or CD4+ T-cell de-immunized, 2) comprise embedded T-cell epitopes, and / or 3) comprises toxin effectors which retain toxin functions.

The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.

Methods, compounds, compositions, kits and articles of manufacture comprising anti-connexin agents for treatment of orthopedic disorders, diseases, or conditions, and improving recoveries and outcomes of orthopedic procedures or surgeries.

The present invention describes compositions of thymus derived peptides and uses therefore in diagnostic methods and for the treatment of diseases associated with reduced T helper cell counts, diseases such as infection, e.g., HIV infection and other viral infections, parasitic, and bacterial infection, AIDS, ARC, multiple sclerosis, chronic fatigue syndrome, rheumatoid arthritis, Alzheimer's disease, asthma, allergy, dermatitis, type 1 diabetes mellitus, colitis, inflammatory bowel disease / irritable bowel syndrome, Crohn's disease, Psoriasis, Chronic obstructive pulmonary disease, Systemic lupus erythematosus, transplant rejection and cancer.

The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.

The invention relates to a doctor-patient matching method based on a Bayesian network, and the method comprises the steps: S1, collecting electronic medical record data, determining disease and symptom nodes and values thereof, and enabling the disease and symptom nodes to serve as training set data; S2, constructing a disease-disease / disease-symptom self-interaction matrix, and taking the disease-disease / disease-symptom self-interaction matrix as a constraint of a Bayesian network; S3, constructing a Bayesian network model, and performing structure learning and parameter learning; S4, inputting the disease into the Bayesian network pre-diagnosis model by the patient to obtain all possible disease combinations for calculating the complication of the main disease and the complication; S5, calculating a matching index of doctors and patients; S6, constructing a doctor recommendation model based on the matching index of the doctors and the patients; and S7, obtaining the optimal allocation of the patients and the doctors according to the preference index of the patient. According to the invention, doctor-patient matching is carried out by combining the pre-diagnosis result, the doctorspecialty, the doctor workload and the patient preference, and the defect that the current doctor-patient matching technology is not accurate enough is solved.

The system disclosed allows a user to specify an illness, disease, or health condition, mental or physical or otherwise, and interconnect with other users having similar diagnoses, symptoms, conditions, complications, treatments, or otherwise. The patient user may be connected to a caregiver who links into the system to connect with other caregivers as well. The social network is a health web designed to interconnect patients, friends, families, doctors or others who seek personalized medical information pertaining to the experiences of others. The system allows an interconnection of patients who want to correspond as to symptoms and treatments, and / or for medical professionals who seek to expand their global knowledge base as to collegial networks for diagnosis, treatment, and real-time evaluation. The social network provides a global interface, connected via mobile device, remotely for medical treatment globally, from the latest innovations in medicine to the remote locations of the world.

The invention relates to a medicament for treating or preventing coronary disease, angor pectoris, myocardial infarction, arrhythmia, ischemic brain disease, cerebral thrombosis, cerebral hemorrhage and sequelae thereof, vascular dementia and peripheral circulation disturbance disease, including various artery occlusions, vasculitis, and microcirculatory disturbance caused by diabetes mellitus, high blood pressure, hyperlipidemia and hyperviscosity as well as refractory neck syndrome, vertebrobasilar artery insufficiency and other ischemic diseases accompanying with microcirculatory disturbance, namely, a scutellarin derivative and preparation and application thereof. The derivative has high storing stability, and is suitable for preparing a medicament for treating or preventing heart cerebrovascular diseases.

The system disclosed allows a user to specify an illness, disease, or health condition, mental or physical or otherwise, and interconnect with other users having similar diagnoses, symptoms, conditions, complications, treatments, or otherwise. The patient user may be connected to a caregiver who links into the system to connect with other caregivers as well. The social network is a health web designed to interconnect patients, friends, families, doctors or others who seek personalized medical information pertaining to the experiences of others. The system allows an interconnection of patients who want to correspond as to symptoms and treatments, and / or for medical professionals who seek to expand their global knowledge base as to collegial networks for diagnosis, treatment, and real-time evaluation. The social network provides a global interface, connected via mobile device, remotely for medical treatment globally, from the latest innovations in medicine to the remote locations of the world.

A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and / or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising an anticholinergic bronchodilator for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases.

The invention relates to the treatment or prevention of an inflammatory skin disease, disorder or condition, by modulating a protein that is normally regulated by caspase-8 in the skin or by increasing caspase-8 activity or level in the skin. Another aspect of the invention relates to methods for diagnosing an inflammatory skin disease, disorder or condition or a predisposition to develop said disease disorder or condition in an individual. Further aspects of the invention relate to methods for identifying target proteins involved in the course or pathology of an inflammatory skin disease, disorder or condition and to methods of screening a candidate compound for treating said disease, disorder or condition. In particular, the invention relates to inflammatory skin diseases such as atopic dermatitis and psoriasis.

A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and / or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising a lipoxygenase inhibitor for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases.

The invention relates to novel heparanases, heparanase splice variants, and to polynucleotides encoding them. Particularly, the invention relates to Spalax heparanases, and to Spalax and human heparanase splice variants. Heparanase splice variants can be used, for example, to modulate the activity of heparanase in diseases disorders or conditions caused by or associated with the enzymatic activity of heparanase. For instance, a splice variant capable of down regulating the activity of heparanase can be used to treat primary tumors and / or to prevent or treat metastasis.

Compounds that inhibit HIF-2α, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2α.

The invention relates to naphthalene compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine for the treatment of diseases, disorders associated with the modulation of calcium sensing receptor modulators (Ca SR). The invention also relates to pharmaceutical compositions containing such compounds in treating diseases disorders associated with calcium sensing receptor modulators (Ca SR) channel modulators.

The invention relates to a monoclonal antibody capable of neutralizing CYR61 and applications thereof and a hybrid tumor capable of generating the monoclonal antibody. The technical scheme adopted by the invention relates to the monoclonal antibody secreted by the mouse anti-human CYR61 monoclonal antibody hybrid tumor CGMCC No.2766 or CGMCC No.2767, and the applications of the monoclonal antibody to preparation of a medicament for treating rheumatic disease, wherein the rheumatic disease is the chronic infectious arthritis. The invention has the advantages that: (1) the self-prepared monoclonal antibody can research pathogenesis of CYR61 in rheumatoid arthritis and can accurately position the expression of CYR61 and detect the CYR61 level of the blood serum and the lesion sites (such as joints); (2) the monoclonal antibody can be used for preparing a detection kit so as to distinguish clinical diagnostics of osteoarthritis and rheumatoid arthritis; and (3) the monoclonal antibody also can search the combination epitope where the CYR61 on the surface of the synovium and in the synovial of the rheumatoid arthritis patient can be neutralized, and provides the screening basis for preparing a humanized antibody which can neutralize the CYR61 in the next step.

The invention relates to the treatment or prevention of an inflammatory skin disease, disorder or condition, by modulating a protein that is normally regulated by caspase-8 in the skin or by increasing caspase-8 activity or level in the skin. Another aspect of the invention relates to methods for diagnosing an inflammatory skin disease, disorder or condition or a predisposition to develop said disease disorder or condition in an individual. Further aspects of the invention relate to methods for identifying target proteins involved in the course or pathology of an inflammatory skin disease, disorder or condition and to methods of screening a candidate compound for treating said disease, disorder or condition. In particular, the invention relates to inflammatory skin diseases such as atopic dermatitis and psoriasis.

Use of soluble CD14 (sCD14) for the manufacture of a medicament for therapeutic or preventive treatment of a disease involving a chronic inflammation condition and a clinical disorder associated with insulin resistance in an animal or a human. Examples of diseases include type 2 diabetes mellitus, obesity, metabolic syndrome, arteriosclerotic disease, arterial hypertension and functional ovaric hyperandrogenism.

The present invention relates to a doctor-patient matching method based on Bayesian network, comprising: step S1: collect electronic medical record data, determine disease and symptom nodes and their values, and use them as training set data; step S2: construct 'disease-disease' / disease-symptom' self-interaction matrix, and as a constraint of the Bayesian network; step S3: construct the Bayesian network model, and perform structure learning and parameter learning; step S4: the patient enters the disease into the Bayesian network pre-diagnosis model , to obtain all possible disease combinations that calculate the main disease and complications concurrently; step S5 calculates the matching index of the doctor and the patient; step S6: constructs a doctor recommendation model based on the matching index of the doctor and the patient; Optimal distribution with physicians. The invention combines the pre-diagnosis results, doctor's expertise, doctor's workload and patient preference to perform doctor-patient matching, and solves the defect that the current doctor-patient matching technology is not accurate enough.

A composition including a mixture of: (a) first nanoparticle carrier vehicles loaded with an active ingredient for treating or preventing a disorder (therapeutic nanoparticles), and (b) second nanoparticle carrier vehicles without the active ingredient (decoy nanoparticles). Also method of treating or preventing a disease, disorder or condition comprising administering to a human subject in need a dose of a composition having nanoparticles containing an active ingredient effective to treat or prevent the disease, disorder or condition. The dose is in terms of number of nanoparticles, and the nanoparticles is one of gold nanoparticles, liposomes, silica nanoparticles, micelles, hydrogels or polymeric nanoparticles. The number of nanoparticles in the dose is of at least one and one-half (1.5) quadrillion (1015) nanoparticles.

The invention provides a disease-microorganism association prediction system based on projection and comparative learning, and the system comprises a data obtaining module which is configured to obtain disease and microorganism parameter data; the unweighted projection module is configured to perform unweighted projection on a bipartite network constructed according to the parameter data to obtain a disease-disease association and a disease-microorganism association; the feature extraction module is configured to obtain disease features according to disease-disease association and disease association graph comparative learning, and obtain microorganism features according to disease-microorganism association and microorganism association graph comparative learning; the association prediction module is configured to obtain a disease-microorganism association prediction result according to the disease characteristics, the microorganism characteristics and a preset full-connection network model; according to the invention, based on projection and graph mutual information comparison learning, faster and more accurate prediction of disease-microorganism association is realized.